Telix Pharmaceuticals Ltd
ASX:TLX
Telix Pharmaceuticals Ltd
Revenue
Telix Pharmaceuticals Ltd
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Revenue
AU$502.5m
|
CAGR 3-Years
359%
|
CAGR 5-Years
381%
|
CAGR 10-Years
N/A
|
|
Immutep Ltd
ASX:IMM
|
Revenue
AU$256.6k
|
CAGR 3-Years
-61%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
-24%
|
|
Mesoblast Ltd
ASX:MSB
|
Revenue
$7.5m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
CSL Ltd
ASX:CSL
|
Revenue
$14.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
10%
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
Revenue
AU$87.3m
|
CAGR 3-Years
31%
|
CAGR 5-Years
25%
|
CAGR 10-Years
42%
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Revenue
AU$21.5m
|
CAGR 3-Years
99%
|
CAGR 5-Years
377%
|
CAGR 10-Years
32%
|
See Also
What is Telix Pharmaceuticals Ltd's Revenue?
Revenue
502.5m
AUD
Based on the financial report for Dec 31, 2023, Telix Pharmaceuticals Ltd's Revenue amounts to 502.5m AUD.
What is Telix Pharmaceuticals Ltd's Revenue growth rate?
Revenue CAGR 5Y
381%
Over the last year, the Revenue growth was 214%. The average annual Revenue growth rates for Telix Pharmaceuticals Ltd have been 359% over the past three years , 381% over the past five years .